Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in high-risk Stage III melanoma
NCT02362594Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in melanoma, sponsored by Merck & Co. Primary endpoints: Recurrence-Free Survival At 6 Months Among All Participants and Recurrence-Free Survival At 6 Months Among Participants With PD-L1-positive Tumor Expression. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02362594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362594.